Celcuity outlines potential $2.5B annual peak revenue for gedatolisib amid pivotal clinical milestones and commercial launch preparations (NASDAQ:CELC)
CelcuityCelcuity(US:CELC) Seeking Alpha·2026-03-26 00:16

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Celcuity outlines potential $2.5B annual peak revenue for gedatolisib amid pivotal clinical milestones and commercial launch preparations (NASDAQ:CELC) - Reportify